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48 The Journal of Thoracic and Cardiobjective: Because acute rejection is the most important cause of chronic rejection
n lung transplantation, the use of conventional systemic immunosuppression to
mprove long-term survival needs to be reassessed. The aim of this study was to
nvestigate the efficacy and safety of inhaled tacrolimus for preventing acute
ejection of rat lung allografts.
ethods: Orthotopic left lung transplantation was performed in rats that were
ivided into 6 groups: control group received no treatment; groups 1.0-IM, 0.5-IM,
nd 0.3-IM received tacrolimus by intramuscular injection at 1.0, 0.5, and 0.3
g/(kg · d), respectively; and groups 12-IT and 6-IT received 12 and 6 puffs of
nhaled tacrolimus 3 times per day, respectively. Allografts were studied histolog-
cally. Whole blood and allograft tacrolimus concentrations were determined.
esults: In groups 1.0-IM and 12-IT, histologic grade of the graft showed signifi-
antly less rejection than in the other groups. The blood tacrolimus concentration in
roup 12-IT (4.87 ng/mL) was significantly lower than that in group 1.0-IM (13.05
g/mL, P  .0017) on postoperative day 7. Higher allograft tacrolimus concentra-
ions were achieved in group 1.0-IM (478.0 ng/g) than in group 12-IT (270.4 ng/g,
 .009). Weight loss and diarrhea in group 12-IT were less severe than in the
roups that received systemic tacrolimus. The proliferating cell nuclear antigen
ndex in bronchus-associated lymphoid tissue cells was significantly lower in group
2-IT than in group 1.0-IM (P  .0209).
onclusion: Local immunotherapy with inhaled tacrolimus has great potential for
ontrolling pulmonary allograft rejection in clinical lung transplantation because it
as fewer side effects than systemic immunosuppressive agents.
espite the fact that lung transplantation is an accepted and established
therapeutic option for a variety of end-stage lung diseases,1,2 chronic
rejection, as manifested by obliterative bronchiolitis, is a limiting factor for
chieving adequate long-term survival. Because acute rejection is the most impor-
ant cause of chronic rejection, initial immunosuppression regimens that are based
n cyclosporine (INN ciclosporin) or tacrolimus may have a significant impact on
ong-term allograft function. Several reports have found that patients who receive
acrolimus-based therapy appear to have immunosuppressive advantages similar to
r slightly better than those of patients treated with cyclosporine.3-8 Tacrolimus has
lso been proven to be beneficial in the management of bronchiolitis obliterans
yndrome as rescue therapy.9-11 Because the incidences among transplant recipients
f infections, nephrotoxicity, diabetes, hypertension, and solid organ tumors are
ignificant, the adverse effects of systemic immunosuppression are a serious
roblem.5,6,8
Ideal immunosuppression depends on two basic concepts. The first is the need to
ontrol early intragraft immune events directly; the second is the need to achieve
vascular Surgery ● February 2007
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TXigh local drug delivery while diminishing the adverse
onsequences of systemic immunosuppression. Lung tissue
ffers a unique opportunity to study the efficacy of local
mmunosuppression because of the ease with which air-
orne drugs may be deposited in the allograft by inhala-
ion.12 Aerosolized cyclosporine has been used at the Uni-
ersity of Pittsburgh Medical Center since 1993 as a rescue
herapy for patients with lung acute rejection and appears to
e effective in refractory chronic rejection.13-15 There have
een few reports, however, regarding the usefulness of
nhaled tacrolimus in lung transplantation.16 A prospective,
andomized trial demonstrated that inhaled tacrolimus had a
reater immunosuppressive potential than cyclosporine with
espect to both acute and chronic rejection.17 We therefore
ypothesized that inhaled tacrolimus represents an alterna-
ive drug delivery system that might be ideal for successful
ung transplantation. The aim of this study was to determine
hether inhaled tacrolimus would prevent acute rejection of
at lung allografts and would provide effective graft con-
entrations with low systemic delivery in recipient rats
elative to the intramuscular administration of tacrolimus.
aterials and Methods
nimals
dult male inbred rats, 8 to 12 weeks old, were used for all the
xperiments. Transplantations were done with Brown Norway rats
eighing 200 to 250 g as donors (SLC, Japan) and Lewis rats
eighing 250 to 300 g as recipients (Charles River Japan, Yoko-
ama, Japan).
ung Transplantation
nilateral orthotopic left lung transplantation was performed with
he cuff technique, as described previously.18 The cold lung isch-
mic time ranged from 25 to 40 minutes. No antibiotic prophylaxis
as given after the operation. All animals received humane care in
ompliance with the Guide for the Care and Use of Laboratory
nimals of Nagasaki University.
mmunosuppressive Drug and Administration
acrolimus 0.1% as an inhalant and in powder form was provided
s a gift by Astellas Pharma Inc, Tokyo, Japan. The tacrolimus
owder was dissolved in saline solution for intramuscular injec-
ion. For the administration of inhaled tacrolimus, we used a
ouble chamber (BUXCO Electronics, Inc, Osaka, Japan) to en-
ure that the animals were exposed to the drug (Figure 1). The
hamber had separate head and body compartments, separated by
Abbreviations and Acronyms
BALT  bronchus-associated lymphoid tissue
PCNA proliferating cell nuclear antigen
POD  postoperative dayneck seal. The animal was placed in the chamber for 2 minutes, w
The Journal of Thoracicnd inhaled tacrolimus (50 g/puff) was sprayed through the port
ocated in the front wall of the head chamber.
xperimental Groups and Immunosuppressive
herapy
ecipients were divided into 6 experimental groups. The control
roup (n  7) received no immunosuppressant. Group 1.0-IM
n  7) received tacrolimus in powder form dissolved in saline
olution by intramuscular injection at a dosage of 1 mg/(kg · d);
roup 0.5-IM (n  7) received tacrolimus in powder form dis-
olved in saline solution by intramuscular injection at a dosage of
.5 mg/(kg · d); and group 0.3-IM (n  7) received tacrolimus in
owder form dissolved in saline solution by intramuscular injec-
ion at a dosage of 0.3 mg/(kg · d). All animals received the first
ssigned tacrolimus dose within 1 hour of transplantation on
ostoperative day (POD) 0. The same dose was dispensed every 24
ours until the animal was killed. The last intramuscular tacroli-
us dose was given 24 hours before the animal was killed, and the
pecimens were harvested immediately thereafter. Group 12-IT
n  7) received 12 puffs of 0.1% inhaled tacrolimus 3 times per
ay. Group 6-IT (n  7) received 6 puffs of 0.1 % inhaled
acrolimus 3 times per day. The last inhaled tacrolimus dose was
dministered 1 hour before the animal was killed. All recipients
ere killed on POD 7.
istologic Analysis
ll allografts and native lungs were divided after being harvested
nd were preserved in 4% paraformaldehyde in a phosphate-
uffered saline solution. The specimens were embedded in paraf-
n, sectioned, stained with hematoxylin and eosin, and graded in
blinded fashion with the Yousem standardized nomenclature for
ung allograft rejection.19 In brief, the grading scale was as fol-
ows: grade 0, no cellular infiltrates; grade 1, perivascular infil-
rates of small round and transformed large lymphoid cells and
mmunoblasts and endothelitis; grade 2, perivascular mononuclear
nfiltrates with spread into adjacent alveolar septae and prominent
lveolar macrophages; grade 3, perivascular mononuclear infiltrate
igure 1. Double chamber was used to administer inhaled ta-
rolimus to ensure animals were exposed to appropriate dose.ith peribronchiolar inflammation, lymphocyte epidermotropism,
and Cardiovascular Surgery ● Volume 133, Number 2 549
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TXpithelial cell and alveolar pneumocyte necrosis, diffuse interstitial
neumonitis, hyaline membranes, and intra-alveolar accumulation
f neutrophils and macrophages; grade 4, vascular thrombosis with
assive intra-alveolar hemorrhage and infarction and diffuse in-
erstitial pneumonia with diffuse alveolar damage.
easurement of Tacrolimus
acrolimus concentrations in whole blood and in homogenates of
he allograft lungs were measured by the microparticle enzyme
mmunoassay method based on the Abbott IMX analyzer (Abbott
aboratories, Abbott Park, Ill).20 Briefly, the microparticle enzyme
mmunoassay is a semiautomated immunoassay with a manual
retreatment step in which the sample is extracted with a precip-
tation reagent and centrifuged. The supernatant is entered into the
mmunoassay process, and the final fluorescent product is mea-
ured with the IMX analyzer. Tacrolimus concentrations in the
omogenates of allograft lungs were measured with the same
ethod.
roliferating Cell Nuclear Antigen Staining
roliferating cell nuclear antigen (PCNA) immunohistochemi-
al staining was performed with a monoclonal murine antibody,
C10 (immunoglobulin G2a; DAKO A/S, Glostrup, Denmark)
t a dilution of 1:100. The antibody, diluted with 0.05-mol/L
ris(hydroxymethyl)aminomethane hydrochloride buffer, was ap-
lied to the deparaffinized tissue sections. The binding of PC10
as detected with the biotinylated secondary antibody and with
eroxidase-labeled streptavidin (DAKO Corporation, Carpinteria,
alif). The sections were visualized with diaminobenzidine, and
he nuclei were then stained with hematoxylin. Sections that were
ncubated with normal mouse immunoglobulin G, instead of the
rimary antibody, served as negative controls. The bronchus-
ssociated lymphoid tissue (BALT) cells in the allograft were
xamined and classified as positive for PCNA (red nuclei from fast
ed staining) or negative PCNA (blue nuclei from hematoxylin
taining). The PCNA index (percentage of PCNA-positive nuclei)
as determined from counts of more than 1000 cells. The BALT
ell PCNA indices obtained for each group were compared.
tatistical Analysis
omparisons of the grade of rejection among the experimental
roups were made with the Mann–Whitney U test. Unpaired 1
50 The Journal of Thoracic and Cardiovascular Surgery ● Febrtudent t-tests were used to compare blood or tissue tacrolimus
oncentrations among the experimental groups. Data are expressed
s mean  SD.
esults
ith respect to the grading of rejection, all control group
nimals showed grade 4 severe destructive change of pulmo-
ary rejection on POD 7. Animals in group 1.0-IM had a mean
ejection grade of 0.71  0.48, those in group 0.5-IM had a
ean grade of 2.28  0.48, and those in group 0.3-IM had
mean grade of 3.71  0.48. Animals in group 12-IT
howed minimal changes with a mean rejection grade of
.42  0.53; those in group 6-IT showed intense perivas-
ular infiltrates with a mean rejection grade of 3.60  0.54.
igure 2 shows the rejection grade for each group. There
ere no significant differences among the control, 0.3-IM,
nd 6-IT groups. Animals in groups 1.0-IM and 12-IT
howed significantly less rejection than in the other groups
P  .01).
To confirm that there was no transient elevation of blood
acrolimus concentration levels in the inhaled tacrolimus
roup, the last time that the dose was given was taken into
ccount separately for both the inhaled and systemic groups.
hus in group 12-IT the blood and allograft tacrolimus
oncentrations were measured 1 hour after each dose was
iven (3 times per day), and in group 1.0-IM they were
easured 24 hours after the last dose. Whole blood tacroli-
us concentrations on POD 7 (Figure 3) were 13.05  4.65
g/mL in group 1.0-IM, 7.88  0.84 ng/mL in group
.5-IM, 4.45  1.88 ng/mL in group 0.3-IM, 4.87  1.39
g/mL in group 12-IT, and 2.40  0.63 ng/mL in group
-IT. Blood tacrolimus concentration was significantly
ower in group 12-IT than in groups 1.0-IM (P .0017) and
.5-IM (P .0033). The allograft tacrolimus concentrations
n POD 7 (Figure 4) were 478.0  43.2 ng/g in group
.0-IM, 233.7  40.5 ng/g in group 0.5-IM, 147.5  13.7
g/g in group 0.3-IM, and 270.4  21.1 ng/g in group
Figure 2. Rejection grade on POD 7. Differences
among control, 0.3-IM, and 3-IT groups were not
significant. In groups 1.0-IM and 12-IT, histologic
grade of the graft showed significantly less re-
jection than in other groups (P < .01).2-IT. Higher allograft tacrolimus concentrations were
uary 2007
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TXchieved in group 1.0-IM than in group 0.5-IM (P  .009)
nd group 12-IT (P  .009).
Weight loss and diarrhea were common side effects.
eight losses were 26.6  5.7 g in the control group, 50 
0.0 g in group 1.0-IM, 40  8.1 g in group 0.5-IM, 22.5 
4.6 g in group 0.3-IM, 20.0  8.6 g in group 12-IT, and
6.0  5.4 g in group 6-IT. Weight loss in group 12-IT was
ess severe than in groups 1.0-IM (P  .0014) and 0.5-IM
P  .0015). All group 1.0-IM rats had diarrhea. Five of
even animals (71.4%) in group 0.5-IM and 1 of 7 (14.3%)
n groups 0.3-IM and group 12-IT had diarrhea. No animals
n the control and 6-IT groups had diarrhea. Diarrhea in
roup 12-IT was less severe than in groups 1.0-IM (P 
0018) and 0.5-IM (P  .0374).
On POD 7, the BALT cell PCNA indices in the allo-
rafts were 21.3%  7.8% in group 1.0-IM (Figure 5, A ),
6.2%  6.3% in group 0.5-IM, and 6.3%  2.2% in
roup 12-IT (Figure 5, B ). The BALT cell PCNA index
as significantly lower in group 12-IT than in groups
.0-IM (P  .0209) and 0.5-IM (P  .0209, Figure 6).
iscussion
he current success of lung transplantation is largely attrib-
table to the effectiveness of immunosuppressive therapy.
he inconsistent control of acute rejection by systemic
mmunosuppression, however, which is almost universally
redictable after lung transplantation, is still a major cause
f low 5-year survival.21 Despite enhanced immunosuppres-
ion, a subset of patients have refractory acute rejection, and
early 50% of lung transplant recipients have obliterative
ronchiolitis develop.22 In addition, long-term use of sys-
emic immunosuppression has resulted in significant drug-
igure 3. Tacrolimus (FK506) concentrations in whole blood were
easured with microparticle enzyme immunoassay method.elated morbidity.5,6,8 f
The Journal of ThoracicSince 1993, aerosolized cyclosporine has been used at
he University of Pittsburgh Medical Center as a rescue
herapy for patients with lung rejection, and it appears to be
ffective in reversing rejection.13-15 Recently, a randomized
rial of inhaled cyclosporine in lung transplant recipients
ndicated that inhaled cyclosporine improved survival and
xtended the period of chronic rejection-free survival with-
ut improving the rate of acute rejection.23 Increasing evi-
ence suggests that the acute rejection process is initiated
nd modulated locally within the allograft. Alloactivation
y major histocompatibility complex antigens on passenger
eukocytes in the graft provokes an intense inflammatory
eaction, resulting in a rapid influx of neutrophils and mac-
ophages. The subsequent release of cytokines and nitric
xide promotes local macrophage amplification and donor-
pecific T- and B-cell clonal expansion. Thus regional im-
unotherapy is a logical approach for achieving early high
ocal drug levels that would inhibit the expression of allo-
raft recognition targets, cytokine release, and effector cell
unction and migration to the allograft.24 Iacono and col-
eagues14 demonstrated that aerosolized cyclosporine re-
uced interleukin-6 messenger RNA expression by lung
raft bronchoalveolar lavage cells.
Prop and associates25 have suggested that the BALT
agnifies the interaction between the pulmonary graft and
he recipient host that likely accelerates the induction of the
ejection response, both locally in the graft and systemi-
ally, in the recipient’s lymphoid organs. Our group has
reviously found the expression of PCNA to be associated
ith acute cellular rejection of the bronchial epithelium and
he BALT cells. In this study, we found that aerosol tacroli-
us effectively suppresses the expression of PCNA in
ALT cells. Furthermore, at the alveolar level, there were
igure 4. Tacrolimus (FK506) concentrations in homogenates of
llograft lungs were measured with microparticle enzyme immu-
oassay method.ewer PCNA-positive infiltrating cells in the inhaled tacroli-
and Cardiovascular Surgery ● Volume 133, Number 2 551
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TXus group than in the systemic tacrolimus group (data not
hown). Thus it would appear that inhaled tacrolimus might
ave different mechanisms from systemic tacrolimus for the
ocal control of the interaction between pulmonary graft
ells and the infiltrating recipient cells.
To control acute pulmonary rejection, a timed dosage of
2 puffs of tacrolimus was required 3 times per day, which
esulted in a daily tacrolimus dose of 1.8 mg. Ingu and
olleagues16 demonstrated that 10 puffs of inhaled tacroli-
us and the intramuscular administration of 1.0 mg/(kg · d) of
acrolimus had similar degrees of effectiveness in the same
nimal models. In our preliminary study, however, a single
aily dosage of 12 puffs of tacrolimus was not found to be
ffective. Although a double-chamber system was useful for
xposing the animals to the drug, the dead space of the
hamber makes it difficult to determine the precise inhala-
ion volume from the animals’ airways. Furthermore, the
igure 5. Proliferating cell nuclear antigen staining with la-
eled streptavidin biotin–alkaline phosphatase enzyme system
n bronchus-associated lymphoid tissue cells present in allo-
rafts on postoperative day 7. A, Proliferating cell nuclear
ntigen–positive cells are present in bronchus-associated
ymphoid tissue of animal from group 1.0-IM. B, Proliferating
ell nuclear antigen–positive cells are rarely observed in
ronchus-associated lymphoid tissue of animal from group
2-IT. Brown dots indicate proliferating cell nuclear antigen.ffect of reperfusion injury, the status of bronchial anasto- l
52 The Journal of Thoracic and Cardiovascular Surgery ● Febrosis, and the impairment of mucociliary function might
ffect the inhalation efficiency of the lung allograft.
Infections and side effects remain important issues with
ystemic immunosuppression. Although the incidences of
nfections in tacrolimus- and cyclosporine-treated recipients
ere found to be similar, there was a trend toward more fungal
nfections in the tacrolimus group.7 Furthermore, although
he incidence of drug-related side effects were similar in the
wo groups, new-onset diabetes mellitus requiring antidia-
etic medication was a side effect that was characteristically
ound in the tacrolimus group.8 Our study highlights the
afety of inhaled tacrolimus, which is associated with less
ystemic toxicity than is intramuscular tacrolimus. The
eight loss and diarrhea seen in group 12-IT were signifi-
antly less severe than in group 1.0-IM. In group 12-IT, the
lood and allograft tacrolimus concentrations were mea-
ured 1 hour after each dose was given (3 times per day) and
ere found to be lower than the blood and allograft tacroli-
us concentrations in group 1.0-IM 24 hours after the last
ose. This indicates that the high dose of inhaled tacrolimus
bsorbed from the airway surface did not directly increase
lood tacrolimus levels, whereas the high dose of systemic
acrolimus continued to increase blood and allograft tacroli-
us levels. These results strongly suggest that inhaled ta-
rolimus is superior to systemic tacrolimus with respect to
ecreasing the incidence of side effects.
In conclusion, we found that inhaled tacrolimus used as
ocal immunotherapy prevented acute rejection and offered
ffective allograft tacrolimus concentrations with low sys-
emic drug delivery. Thus inhaled tacrolimus has great
linical potential to control and treat pulmonary rejection in
igure 6. Bronchus-associated lymphoid tissue cell proliferating
ell nuclear antigen index of allografts on postoperative day 7.
ronchus-associated lymphoid tissue cell proliferating cell nu-
lear antigen index was significantly lower in group 12-IT than in
roups 1.0-IM (P  .0209) and 0.5-IM (P  .0209).ung allograft recipients. As has been seen with aerosolized
uary 2007
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reating and preventing obliterative bronchiolitis.26
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